核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理

参加乙型肝炎耐药讨论会专家

核苷和核苷酸类药物治疗慢性乙型肝炎的耐药及其管理

参加乙型肝炎耐药讨论会专家

详细信息

中图分类号: R512.62
计量
- 文章访问数: 5157
- HTML全文浏览量: 14
- PDF下载量: 1574
- 被引次数: 0
出版历程
- 出版日期: 2013-01-20

Drug resistance to nucleoside and nucleotide analogs in chronic hepatitis B and its management

Experts Attending the Disscussion on Hepatitis B Virus Drug Resistance

摘要

摘要:
<正>在核苷和核苷酸类药物（nucleoside and nucleotide ana-logs,NAs）治疗慢性乙型肝炎过程中,耐药是一个极为重要的问题。与未发生耐药的患者比较,耐药不仅可导致疾病进一步进展,并可增加发生肝功能失代偿和肝细胞癌（HCC）的风险;还会加大后续治疗的难度,增加长期治疗的医疗成本。
- 肝炎,乙型,慢性 /
- 抗药性 /
- 核苷和核苷酸类药物 /
- 管理
- hepatitis B /
- chronic /
- drug resistance /
- nucleoside and nucleotide analogs

HTML全文

参考文献(78)

[1] 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].中国病毒病杂志, 2011, 1 (1) :9-23.

[2] European Association for the Study of the Liver.EASL clinicalpractice guidelines:management of chronic hepatitis B virusinfection[J].J Hepatol, 2012, 57 (1) :167-185.

[3]Liaw YF, Kao JH, Piratvisuth T, et al.Asian-Pacific consensusstatement on the management of chronic hepatitis B:a 2012update[J].Hepatol Int, 2012, 6 (3) :531-561.

[4] Lok AS, McMahon BJ.Chronic hepatitis B:update 2009[J].Hepatology, 2009, 50 (3) :661-662.

[5]乙型肝炎病毒耐药专家委员会.乙型肝炎病毒耐药专家共识[J/CD].中华实验和临床感染病杂志, 2008, 2 (1) :90-98.

[6] 乙型肝炎病毒耐药专家委员会.乙型肝炎病毒耐药专家共识:2009年更新[J/CD].中华实验和临床感染病杂志, 2009, 3 (1) :72-79.

[7] Yao GB, Zhu M, Cui ZY.A 7-year study of lamivudine ther-apy for hepatitis B virus e antigen-positive chronic hepatitisB patients in China[J].J Dig Dis, 2009, 10 (2) :131-137.

[8] Lai CL, Dienstag J, Schiff E, et al.Prevalence and clinicalcorrelates of YMDD variants during lamivudine therapy for pa-tients with chronic hepatitis B[J].Clin Infect Dis, 2003, 36 (6) :687-696.

[9]Papatheodoridis GV, Dimou E, Laras A, et al.Course of vir-ologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease[J].Hepatolo-gy, 2002, 36 (1) :219-226.

[10]Liaw YF, Gane E, Leung N, et al.2-Year GLOBE trial re-sults:telbivudine is superior to lamivudine in patients withchronic hepatitis B[J].Gastroenterology, 2009, 136 (2) :486-495.

[11] Lai CL, Gane E, Liaw YF, et al.Telbivudine versus lamivudi-ne in patients with chronic hepatitis B[J].N Engl J Med, 2007, 357 (25) :2576-2588.

[12]Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al.Long-term therapy with adefovir dipivoxil for HBeAg-negativechronic hepatitis B for up to 5 years[J].Gastroenterology, 2006, 131 (6) :1743-1751.

[13] Marcellin P, Chang TT, Lim SG, et al.Long-term efficacyand safety of adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hepatitis B[J].Hepatology, 2008, 48 (3) :750-758.

[14]Minde Z, Yimin M, Guangbi Y, et al.Five years of treatmentwith adefovir dipivoxil in Chinese patients with HBeAg-positivechronic hepatitis B[J].Liver Int, 2012, 32 (1) :137-146.

[15]Yokosuka O, Takaguchi K, Fujioka S, et al.Long-term useof entecavir in nucleoside-na ve Japanese patients withchronic hepatitis B infection[J].J Hepatology, 2010, 52 (6) :791-799.

[16]Yuen MF, Seto WK, Fung J, et al.Three years of continuousentecavir therapy in treatment-na ve chronic hepatitis B pa-tients:viral suppression, viral resistance and clinical safety[J].Am J Gastroenterol, 2011, 106 (7) :1264-1271.

[17]Snow-Lampart A, Chappell B, Curtis M, et al.No resist-ance to tenofovir disoproxil fumarate detected after up to 144weeks of therapy in patients monoinfected with chronic hep-atitis B virus[J].Hepatology, 2011, 53 (3) :763-773.

[18]孙秘书, 王贵强, 张伟, 等.拉米夫定经治慢性乙型肝炎患者治疗现状调查分析[J].中国预防医学杂志, 2012, 13 (1) :18-22.

[19]Suzuki F, Akuta N, Suzuki Y, et al.Selection of a virus strainresistant to entecavir in a nucleoside-naive patient with hepati-tis B of genotype H[J].J Clin Virol, 2007, 39 (2) :149-152.

[20] Liaw YF, Sung JJ, Chow WC, et al.Lamivudine for patientswith chronic hepatitis B and advanced liver disease[J].NEngl J Med, 2004, 351 (15) :1521-1531.

[21] Sung JJ, Tsoi KK, Wong VW, et al.Meta-analysis:treat-ment of hepatitis B infection reduces risk of hepatocellularcarcinoma[J].Aliment Pharmacol Ther, 2008, 28 (9) :1067-1077.

[22]Di Marco V, Marzano A, Lampertico P, et al.Clinical out-come of HBeAg-negative chronic hepatitis B in relation tovirological response to lamivudine[J].Hepatology, 2004, 40 (4) :883-919.

[23] Hadziyannis SJ, Papatheodoridis GV, Dimou E, et al.Effica-cy of long-term lamivudine monotherapy in patients withhepatitis B e antigen-negative chronic hepatitis B[J].Hep-atology, 2000, 32 (4 Pt 1) :847-851.

[24] Rizzetto M, Tassopoulos NC, Goldin RD, et al.Extended lami-vudine treatment in patients with HBeAg-negative chronic hep-atitis B[J].J Hepatol, 2005, 42 (2) :173-179.

[25]Gish R, Jia JD, Locarnini S, et al.Selection of chronic hepa-titis B therapy with high barrier to resistance.Lancet InfectDis, 2012, 12 (4) :341-353.

[26]Locarnini S.Primary resistance, multidrug resistance and cross-resistance pathways in HBV as a consequence of treatmentfailure[J].Hepatol Int, 2008, 2 (2) :147-151.

[27] Lok AS, Zoulim F, Locarnini S, et al.Antiviral drug-resist-ant HBV:standardization of nomenclature and assays andrecommendations for management[J].Hepatology, 2007, 46 (1) :254-265.

[28] Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al.Viro-logical breakthrough and resistance in patients with chronic hep-atitis B receiving nucleos (t) ide analogues in clinical practice[J].Hepatology, 2011, 53 (6) :1854-1863.

[29]Pawlotsky JM, Dusheiko G, Hatzakis A, et al.Virologic mo-nitoring of hepatitis B virus therapy in clinical trials and prac-tice:recommendations for a standardized approach[J].Gastroenterology, 2008, 134 (2) :405-415.

[30]Liaw YF.Hepatitis flare and hepatitis B e antigen seroconver-sion:implication in anti-hepatitis B virus therapy[J].JGastroenterol Hepatol, 2003, 18 (3) :246-252.

[31]Locarnini S.Molecular virology of hepatitis B virus[J].Se-min Liver Dis, 2004, 24 (Suppl 1) :3-10.

[32]Zoulim F, Locarnini S.Management of treatment failure in chro-nic hepatitis B[J].J Hepatol, 2012, 56 (Suppl 1) :S112-S122.

[33]Ghany M, Liang TJ.Drug targets and molecular mechanismsof drug resistance in chronic hepatitis B[J].Gastroenterolo-gy, 2007, 132 (4) :1574-1585.

[34]Zoulim F.Mechanism of viral persistence and resistance tonucleoside and nucleotide analogs in chronic hepatitis B virusinfection[J].Antiviral Res, 2004, 64 (1) :1-15.

[35] Locarnini S.Hepatitis B viral resistance:mechanisms and di-agnosis[J].J Hepatol, 2003, 39 (Suppl 1) :S124-S132.

[36]Zeuzem S, Gane E, Liaw YF, et al.Baseline characteristicsand early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B[J].JHepatol, 2009, 51 (1) :11-20.

[37] Liu F, Chen L, Yu DM, et al.Evolutionary patterns of hepati-tis B virus quasispecies under different selective pressures:correlation with antiviral efficacy[J].Gut, 2011, 60 (9) :1269-1277.

[38] Chen L, Zhang Q, Yu DM, et al.Early changes of hepatitisB virus quasispecies during lamivudine treatment and the cor-relation with antiviral efficacy[J].J Hepatol, 2009, 50 (5) :895-905.

[39] Xu Z, Liu Y, Xu T, et al.Acute hepatitis B infection associat-ed with drug-resistant hepatitis B virus[J].J Clin Virol, 2010, 48 (4) :270-274.

[40]Fung SK, Mazzulli T, Sherman M, et al.Pre-existing antivi-ral resistance mutations among treatment-naive HBV pa-tients can be detected by a sensitive line probe assay[J].JHepatol, 2008, 48 (Suppl 2) :S256.

[41]Chotiyaputta W, Hongthanakorn C, Oberhelman K, et al.Ad-herence to nucleos (t) ide analogues for chronic hepatitis B inclinical practice and correlation with virological breakthroughs[J].J Viral Hepat, 2012, 19 (3) :205-212.

[42] Tenney DJ, Levine SM, Rose RE, et al.Clinical emergenceof entecavir-resistant hepatitis B virus requires additionalsubstitutions in virus already resistant to lamivudine[J].An-timicrob Agents Chemother, 2004, 48 (9) :3498-3507.

[43]Villet S, Ollivet A, Pichoud C, et al.Stepwise process for thedevelopment of entecavir resistance in a chronic hepatitis B vi-rus infected patient[J].J Hepatol, 2007, 46 (3) :531-538.

[44]van B mmel F, de Man RA, Wedemeyer H, et al.Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotideanalogues[J].Hepatology, 2010, 51 (1) :73-80.

[45] Patterson SJ, George J, Strasser SI, et al.Tenofovir diso-proxil fumarate rescue therapy following failure of both lami-vudine and adefovir dipivoxil in chronic hepatitis B[J].Gut, 2011, 60 (2) :247-254.

[46]Sheldon J, Camino N, Rodés B, et al.Selection of hepatitis Bvirus polymerase mutations in HIV-coinfected patients treatedwith tenofovir[J].Antivir Ther, 2005, 10 (6) :727-734.

[47] Reijnders JG, Deterding K, Petersen J, et al.Antiviral effect ofentecavir in chronic hepatitis B:influence of prior exposure to nu-cleos (t) ide analogues[J].J Hepatol, 2010, 52 (4) :493-500.

[48]Locarnini SA, Yuen L.Molecular genesis of drug-resistanceand vaccine-escape HBV mutants[J].Antivir Ther, 2010, 15 (3Pt B) :451-461.

[49] Yeh CT.Development of HBV S gene mutants in chronic hepati-tis B patients receiving nucleotide/nucleoside analogue therapy[J].Antivir Ther, 2010, 15 (3 Pt B) :471-475.

[50]Torresi J, Earnest-Silveira L, Deliyannis G, et al.Reducedantigenicity of the hepatitis B virus HBsAg protein arising as aconsequence of sequence changes in the overlapping poly-merase gene that are selected by lamivudine therapy[J].Virology, 2002, 293 (2) :305-313.

[51]Kamili S, Sozzi V, Thompson G, et al.Efficacy of hepatitis Bvaccine against antiviral drug-resistant hepatitis B virus mu-tants in the chimpanzee model[J].Hepatolgy, 2009, 49 (5) :1483-1491.

[52]Warner N, Lorcarnini S.The antiviral drug selected hepatitis Bvirus rtA181T/sW172*mutanbt has a dominant negativesecretion defect and alters the typical profile of viral rebound[J].Hepatology, 2008, 48 (1) :88-98.

[53]Lai MW, Yeh CT.The oncogenic potential of hepatitis B vi-rus rtA181T/surface truncation mutant[J].Antivir Ther, 2008, 13 (7) :875-879.

[54]Lai MW, Huang SF, Hsu CW, et al.Identification of non-sense mutations in hepatitis B virus S gene in patients withhepatiocellullar carcinoma developed after lamivudine therapy[J].Antivir Ther, 2009, 14 (2) :249-261.

[55]Yeh CT, Chen T, Hsu CW, et al.Emergence of the rtA181T/sW172*mutant increased the risk of hepatoma occurrencein patients with lamivudine-resistant chronic hepatitis B[J].BMC Cancer, 2011, 11:398.

[56]Villet S, Pichoud C, Villeneuve JP, et al.Selection of a multipledrug-resistant hepatitis B virus strain in a liver-transplantedpatient[J].Gastroenterology, 2006, 131 (4) :1253-1261.

[57]Yuen MF, Seto WK, Chow DH, et al.Long-term lamivudinetherapy reduces the risk of long-term complications of chronichepatitis B infection even in patients without advanced disease[J].Antivir Ther, 2007, 12 (8) :1295-1303.

[58] Liu Y, Wang C, Zhong Y, et al.Genotypic resistance profileof hepatitis B virus (HBV) in a large cohort of nucleos (t) ideanalogue-experienced Chinese patients with chronic HBVinfection[J].J Viral Hepat, 2011, 18 (4) :e29-e39.

[59]Lok AS, Lai CL, Leung N, et al.Long-term safety of lami-vudine treatment in patients with chronic hepatitis B[J].Gastroenterology, 2003, 125 (6) :1714-1722.

[60] Hongthanakorn C, Chotiyaputta W, Oberhelman K, et al.Viro-logical breakthrough and resistance in patients with chronic hep-atitis B receiving nucleos (t) ide analogues in clinical practice[J].Hepatology, 2011, 53 (6) :1854-1863.

[61] Allen MI, Gauthier J, DesLauriers M, et al.Two sensitivePCR-based methods for detection of hepatitis B virus vari-ants associated with reduced susceptibility to lamivudine[J].J Clin Microbiol, 1999, 37 (10) :3338-3347.

[62] Yim HJ, Hussain M, Liu Y, et al.Evolution of multi-drugresistant hepatitis B virus during sequential therapy[J].Hepatology, 2006, 44 (3) :703-712.

[63] Kim HS, Han KH, Ahn SH, et al.Evaluation of methods for mo-nitoring drug resistance in chronic hepatitis B patients duringlamivudine therapy based on mass spectrometry and reversehybridization[J].Antivir Ther, 2005, 10 (3) :441-449.

[64] Stuyver L, VanGeyt C, DeGendt S, et al.Line probe assayfor monitoring drug resistance in hepatitis B virus-infectedpatients during antiviral therapy[J].J Clin Microbiol, 2000, 38 (2) :702-707.

[65] Lok AS, Zoulim F, Locarnini S, et al.Monitoring drug resist-ance in chronic hepatitis B virus (HBV) -infected patientsduring lamivudine therapy:evaluation of performance of IN-NO-LiPA HBV DR assay[J].J Clin Microbiol, 2002, 40 (10) :3729-3734.

[66]HussainM, Fung S, Libbrecht E, et al.Sensitive line probeassay that simultaneously detects mutations conveying re-sistance to lamivudine and adefovir[J].J Clin Microbiol, 2006, 44 (3) :1094-1097.

[67] Keeffe EB, Dieterich DT, Han SH, et al.A treatment algo-rithm for the management of chronic hepatitis B virus infec-tion in the United States:2008 update[J].Clin Gastroen-terol Hepatol, 2008, 6 (12) :1315-1341.

[68]Hou J, Sun J, Xie Q, et al.Virological breakthrough andgenotypic resistance in a randomized, controlled study on tel-bivudine treatment applying roadmap concept in CHB:W76interim analysis of effort study[J].J Hepatol, 2012, 56 (Suppl 2) :S203-S204.

[69]Zoutendijk R, Reijnders JG, Brown A, et al.Entecavir treat-ment for chronic hepatitis B:adaptation is not needed for themajority of na ve patients with a partial virological response[J].Hepatology, 2011, 54 (2) :443-451.

[70]Sun J, Hou JL, Xie Q, et al.Randomised clinical trial:effi-cacy of peginterferon alfa-2a in HBeAg positive chronic hep-atitis B patients with lamivudine resistance[J].AlimentPharmacol Ther, 2011, 34 (4) :424-431.

[71]Marcellin P, Avila C, Wursthorn K, et al.Telbivudine (LDT) plus peg-interferon (PEGIFN) in HBeAg-positive chronic hep-atitis B-very potent antiviral efficacy but risk of peripheral neu-ropathy (PN) [J].J Hepatol, 2010, 52 (Suppl 1) :S6-S7.

[72] Keeffe EB, Dieterich DT, Pawlotsky JM, et al.Chronic hep-atitis B:preventing, detecting, and managing viral resistance[J].Clin Gastroenterol Hepatol, 2008, 6 (3) :268-274.

[73] Lau GK, Piratvisuth T, Luo KX, et al.Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronichepatitis B[J].N Engl J Med, 2005, 352 (26) :2682-2695.

[74]Sung JJ, Lai JY, Zeuzem S, et al.Lamivudine compared withlamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B[J].J Hepatol, 2008, 48 (5) :728-735.

[75]Lok AS, Trihn HN, Carosi G, et al.Entecavir (ETV) mono-therapy for 96 weeks is comparable to combination therapywith ETV plus tenofovir (TDF) in nucleos (t) ide naive pa-tients with chronic hepatitis B:the BELOW study[J].Hep-atology, 2011, 54 (Suppl 1) :471A.

[76]Terraut NA.Benefits and risks of combination therapy for hepa-titis B[J].Hepatology, 2009, 49 (5 Suppl) :S122-S128.

[77]董南, 何波, 庄辉.慢性乙型肝炎患者对疾病和抗病毒治疗的认知程度调查[J].肝脏, 2009, 14 (1) :8-10.

[78]Wiersma ST, McMahon B, Pawlotsky JM, et al.Treatmentof chronic hepatitis B virus infection in resource-constrainedsettings:expert panel consensus[J].Liver Int, 2011, 31 (6) :755-761.

施引文献

资源附件(0)

访问统计